Adenosine A2A receptor antagonists in neurodegenerative diseases:Huge potential and huge challenges by Franco Fernández, Rafael & Navarro Brugal, Gemma
March 2018 | Volume 9 | Article 681
OpiniOn
published: 12 March 2018
doi: 10.3389/fpsyt.2018.00068
Frontiers in Psychiatry | www.frontiersin.org
Edited by: 
Manuella P. Kaster, 
Universidade Federal de Santa 
Catarina, Brazil
Reviewed by: 
Filipe Marques Goncalves, 
Albert Einstein College of 
Medicine, United States
*Correspondence:
Rafael Franco  
rfranco@ub.edu
Specialty section: 
This article was submitted to 
Neurodegeneration, 
a section of the journal 
Frontiers in Psychiatry
Received: 28 October 2017
Accepted: 19 February 2018
Published: 12 March 2018
Citation: 
Franco R and Navarro G (2018) 
Adenosine A2A Receptor 
Antagonists in Neurodegenerative 
Diseases: Huge Potential and 
Huge Challenges. 
Front. Psychiatry 9:68. 
doi: 10.3389/fpsyt.2018.00068
Adenosine A2A Receptor Antagonists 
in neurodegenerative Diseases: 
Huge potential and Huge Challenges
Rafael Franco1,2* and Gemma Navarro1,3
1 Department of Biochemistry and Molecular Biomedicine, School of Biology, Universidad de Barcelona, Barcelona, Spain, 
2 Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, 
Spain, 3 Department of Biochemistry and Physiology, Faculty of Pharmacy, Universitat de Barcelona, Barcelona, Spain
Keywords: neuroprotection, astroglia and microglia, neuronal death, Alzheimer’s and parkinson’s disease, human, 
clinical trials as topic, caffeine
BACKGROUnD
In this opinion paper, we provide scientific-based reasons about the huge therapeutic potential of 
adenosine A2A receptor antagonists, and about the huge challenges to demonstrate efficacy in clinical 
trials, i.e., to provide data now required to approve a new medication by the regulatory bodies, such 
as U.S. Food and Drug Administration (FDA).
Adenosine is an autacoid present in all tissue and body fluids. Adenosine, whose extracellular 
concentration is controlled by producing/degrading enzymes and by nucleoside transporters, acts 
via four (A1, A2A, A2B, and A3) specific cell surface receptors that belong to the superfamily of 
G-protein-coupled receptors. For decades, adenosine receptors have shown promise as targets 
of medications for a variety of ailments. Until recently, however, the only approved medicine 
was adenosine itself, i.e., the endogenous agonist, to combat arrhythmias, such as paroxysmal 
supraventricular tachycardia (1–3). Prospects are changing as the first medication targeting selec-
tively the adenosine A2A receptor has been approved few years ago in Japan. The recently approved 
drug is an antagonist, i.e., a receptor blocker (see later). A2A receptor antagonists show promise 
in neuroprotection, although for Huntington’s or Niemann Pick’s diseases it is suggested that 
antagonists may be detrimental and/or there is controversy on which is the efficacious interven-
tion, i.e., receptor activation or blockade [see Ref. (4–9) and references therein].
pOTEnTiAL OF A2A RECEpTOR LiGAnDS in THE THERApY  
OF nEURODEGEnERATiVE DiSEASES
At present, not only the A2A receptor (A2AR) is at the center stage for increasing the therapeutic 
tools in a variety of clinical indications, but this opinion paper focuses on the A2AR antagonists, 
which shows promise in immune-mediated control of cancer progression (10–13), in atrial fibril-
lation (14, 15), and in fighting against neurodegenerative diseases (see later). It is relevant that 
virtually all the selective A2AR antagonists whose toxicity has been tested in animal models are very 
safe. Safety has been confirmed in the clinical trials performed using different structures [e.g., Ref. 
(16, 17)]. Istradefylline (KW-6002) is one of the most studied antagonists; it is safe and efficacious 
in Parkinson’s disease. Accordingly, it was approved in Japan in 2013 for adjunctive treatment of 
Parkinson’s patients (under the Nouriast™) (18–20). To our knowledge, up to five clinical trials 
with different antagonists were or are being undertaken (18, 21), but none of them has yet got the 
approval by the U.S. FDA. In our opinion, the two main reasons of the difficulties in translating 
very promising preclinical assays into medications are (i) the tight requirements and (ii) the urgent 
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need of efficacious approaches to assess neurodegeneration/
neuroprotection in humans. It is commented in drug discovery 
forums that quite a number of current drugs could not pass today 
the tight requirements posed by the regulatory bodies. The issue 
of assessing how to measure the neuroprotective efficacy of a 
drug is commented later.
Parkinson’s and Alzheimer’s are the most extended neuro-
degenerative diseases in modern societies with high life expec-
tancy (22, 23). With some exceptions of early-onset symptoms 
(24), age is the main factor for triggering the clinical symptoms 
(25–28). Whereas, Parkinson’s disease patients have successful 
dopamine-replacement therapies and other tools that may be 
used in the disease progression or to decrease the appearance 
of the medication side effects (29–31), Alzheimer’s disease 
patients have not yet got any really efficacious therapeutic 
drug/tool (32, 33).
Clinical manifestation of Parkinson’s disease occurs when 
a significant number of nigral dopamine-producing neurons 
have disappeared. Natural aging leads to 18% of loss of tyrosine 
hydroxylase-positive neurons in the nigra, whereas the degree 
of denervation in patients is very wide, going from 50 to 90%, 
even shortly after diagnosis (34). In this study in post-mortem 
samples, the authors state: “with several of the short-duration 
subjects showing comparable, severe loss of tyrosine hydroxylase-
positive neurons to that seen in subjects 20 years, post-diagnosis” 
(34). The idea behind the use of A2AR antagonists in this disease 
is the adenosine-dopamine antagonism (35–37) in the striatum, 
where the expression of A2ARs is highest in the whole mamma-
lian body (38). Therefore, dopamine-replacement therapy may 
be potentiated by the blockade of the A2AR. Indeed, Nouriast™ 
may serve to achieve efficacy of dopamine-replacement therapies 
at lower levels of dopaminergic drugs, such as levodopa. But 
the key point is that whereas levodopa is not neuroprotective, 
several preclinical assays indicate that A2AR antagonists show 
neuroprotective effects [see Ref. (39–42)]. Moreover, transgenic 
A2AR animals are more resistant to neurodegeneration induced by 
either 1-methyl-4-phenyl-1,2,3,6 tetra-hydropyridine (MPTP)-
induced nigral lesion or focal cerebral ischemia (43–46). Further 
to those preclinical results, epidemiological studies showed that 
caffeine, which is a mixed/non-selective adenosine receptor 
antagonist, decrease the risk of suffering from Parkinson’s or 
from Alzheimer’s diseases [(47, 48); see Ref. (49) and references 
therein for review]. In summary, one challenge for the progres-
sion of A2AR antagonist into approved drugs is to demonstrate 
neuroprotection in humans, for instance to decrease the death 
rate of nigral dopaminergic neurons.
CHALLEnGES in DEVELOpinG 
nEUROpROTECTiVE MEDiCinES
Based on development of our profession of translational research 
we notice that, often, scientific reports do not distinguish among 
symptom improvement and disease modifying drugs. Any drug 
that “improves” the condition of a parkinsonian animal model 
may be considered as neuroprotective. When the drug faces a 
clinical trial with patients, the promoter has to decide between 
analyzing symptom improvement and disease progression as 
primary outcome measure. For reasons further specified below, 
clinical trials for common neurodegenerative diseases analyze 
symptoms as primary outcome with a further difficulty: for 
ethical reasons patients should continue to take the ad  hoc 
medication. Therefore, it is difficult to address whether any new 
medicine is improving symptoms or decreasing the side effects. 
For instance, parkinsonian patients recruited for clinical trials 
continue taking levodopa; thus, the assayed new drug must 
improve symptoms or reduce side effects appearing after years 
of taking levodopa. Difficulties in approving disease modifying, 
i.e., neuroprotective, medication for Parkinson’s were already 
noticed and reviewed years ago (50). Although the issue is on 
the table, to our knowledge there is not any effective action for 
neurodegenerative diseases unlike the case of rare diseases for 
which drug approval may be accelerated. There is an apparent 
lack of consensual rules to evaluate, and consequently approve, 
drugs whose action is to prevent neuronal death, i.e., drugs 
that modify the progression of a neurodegenerative disease. 
Apart from hoping for specific measures tackling this issue at 
the regulatory level, we think that (i) we are quickly moving to 
have reliable neuroprotection biomarkers with positron emis-
sion tomography resolution, i.e., to monitor neurodegeneration 
in vivo in humans and (ii) regulatory bodies should consider 
the approval of the use of safe drugs in healthy cohorts to 
assess the long-term potential as neuroprotectants (assump-
tion would be that drug should delay clinical symptoms and/or 
delay neurodegenerative disease progression). The latter may 
seem risky but, again in our opinion, not riskier than taking 
food supplements or drug supplements to “combat aging,” such 
as testosterone.
CHALLEnGES in DESiGninG 
nEUROpROTECTiVE A2AR AnTAGOniSTS
The two sides of drug action, i.e., addressing symptoms and dis-
ease progression, should be considered for any drug type (A2AR 
antagonists in this article). Whereas in the case of Parkinson’s 
disease, the targets of antagonists in adjunctive treatments of 
dopamine-replacement therapies are A2AR receptors in neu-
rons, the A2A receptor containing targeted cells in the MPTP 
model of Parkinson’s disease that could be responsible for the 
neuroprotective action could not be determined in transgenic 
animals with cell-type-specific (conditional) deletion of the 
receptor (46). In this scenario, and based in convergent and 
wide experimental evidence, we consider that the role of the A2A 
receptor expressed in microglia should not be neglected. Hence, 
another challenge is to select (for a given disease) the receptor to 
be targeted, but also the cell where the receptor must be targeted 
and/or when the receptor of a given cell (neuron or glia) must 
be targeted to afford neuroprotection. Years ago, we found a 
relevant A2AR-related side result on studying gene expression in 
samples from Alzheimer’s patients. Genomics-relevant results 
were upregulation in samples from patients of the Kv3.4 voltage-
gated potassium channel (51) and of the adenosine A1 receptor 
(52). Interestingly, when we moved to perform immunostaining 
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in the cerebral cortex and hippocampus from necropsies of 
Alzheimer’s disease (AD) patients, we confirmed the upregula-
tion of the adenosine A2A receptor concomitant with a change 
in the pattern of expression. The receptor was found inter alia 
in degenerating structures, i.e., in both dystrophic neurites and 
neurons exhibiting neurofibrillary tangles. Whereas, specific 
mRNA expression in the assayed brain areas was not different 
from that found in control samples, the microglial expression 
of the protein was negligible or absent in control samples but 
was evidently expressed in microglial cells in both the cerebral 
cortex and the hippocampus of patients (52).
Function of immune cells in the periphery and of microglia in 
the CNS is regulated by the A2AR. Due to the extensive work of M. 
Sitkovsky’s and other laboratories devoted to targeting adenosine 
receptors to combat cancer, the already promising immuno-
therapy to combat certain tumor types, may be enhanced by the 
blockade of A2AR expressed in immune cells (10–13). Provided 
that ATP is degraded to adenosine in oxygen partial deficiency 
and/or cell death occurring in degenerating environments, 
increased adenosine levels activate upregulated microglial A2ARs. 
Therefore, an obligate drug discovery approach is to target those 
cells and those receptors that promote M2-skewed microglial 
responses.
We highlight microglia as the most likely cell type to be targeted 
(for neuroprotection) by A2AR antagonists. Straightforward data 
in different models, support the view that A2AR activation in glia 
drives neuroinflammation and, therefore, the selective blockade 
of this receptor may be neuroprotective (40, 53–58). We think 
that more experimental effort is required to define when and 
how A2AR antagonists may achieve conversion from M1-skewed 
(proinflammatory) to M2-skewed (neuroprotective) microglia, 
something that requires control of the production of cytokines/
chemokines, interferon-gamma, etc. [see (59) for review]. 
Intrinsic to any transformation, in this case into M1 or into M2 
cells, there is a time window of opportunity whose starting point 
and duration should be also explored. In other words, when to 
start the application of the intervention and when it is too late.
We would like to end this paper with a further opinion, which 
A2AR antagonists may “conceptually” be the new beta-blockers 
(ß-adrenergic antagonists) whose therapeutic potential is vast 
from cardiovascular problems to asthma.
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